In conclusion, the study identified four drugs targeting IL-6, namely, andrographolide, dilmapimod, polaprezinc, and VX-702, which exhibited a docking binding energy < − 6 kcal/mol, indicating their potential role in modulating CSOM progression through IL-6 gene regulation. This evidence concerns the gene IL6 and chronic purulent otitis media.